Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial

Targher, 2013, Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications, J Clin Endocrinol Metab, 98, 483, 10.1210/jc.2012-3093 Marchesini, 2015, NAFLD incidence and remission: only a matter of weight gain and weight loss?, J Hepatol, 62, 15, 10.1016/j.jhep.2014.10.023 Chan, 2003, Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity, Am J Clin Nutr, 77, 300, 10.1093/ajcn/77.2.300 Nascimbeni, 2013, From NAFLD in clinical practice to answers from guidelines, J Hepatol, 59, 859, 10.1016/j.jhep.2013.05.044 Scorletti, 2014, Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the ∗WELCOME study, Hepatology, 60, 1211, 10.1002/hep.27289 Argo, 2015, Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial, J Hepatol, 62, 190, 10.1016/j.jhep.2014.08.036 Nobili, 2011, Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial, Arch Dis Child, 96, 350, 10.1136/adc.2010.192401 Parker, 2012, Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis, J Hepatol, 56, 944, 10.1016/j.jhep.2011.08.018 Sanyal, 2014, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial, Gastroenterology, 147, 377, 10.1053/j.gastro.2014.04.046 Mori, 2006, The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans, Curr Opin Clin Nutr Metab Care, 9, 95, 10.1097/01.mco.0000214566.67439.58 Mori, 2000, Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men, Am J Clin Nutr, 71, 1085, 10.1093/ajcn/71.5.1085 Woodman, 2003, Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients, Atherosclerosis, 166, 85, 10.1016/S0021-9150(02)00307-6 Mesa, 2004, Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein, Atherosclerosis, 175, 333, 10.1016/j.atherosclerosis.2004.04.004 Leigh-Firbank, 2002, Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses, Br J Nutr, 87, 435, 10.1079/BJN2002556 Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257 Mashek, 2014, Serum TAG analysis differentiates between genetic and obesity-associated NAFLD, Diabetes, 63, 42, 10.2337/db13-1500 Hyysalo, 2014, Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity, Diabetes, 63, 312, 10.2337/db13-0774 Farrell, 2010, PNPLeAse get the fats right: does lipogenesis or lipolysis cause NASH?, Hepatology, 52, 818, 10.1002/hep.23867 Pirazzi, 2012, Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro, J Hepatol, 57, 1276, 10.1016/j.jhep.2012.07.030 Ruhanen, 2014, PNPLA3 mediates hepatocyte triacylglycerol remodeling, J Lipid Res, 55, 739, 10.1194/jlr.M046607 Pingitore, 2014, Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function, Biochim Biophys Acta, 1841, 574, 10.1016/j.bbalip.2013.12.006 Mancina, 2015, Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant, J Clin Endocrinol Metab, 100, E821, 10.1210/jc.2014-4464 Peter, 2014, PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans, Diabetologia, 57, 2103, 10.1007/s00125-014-3310-0 Kahali, 2015, TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?, Gastroenterology, 148, 679, 10.1053/j.gastro.2015.01.038 Dongiovanni, 2015, Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, 61, 506, 10.1002/hep.27490 Scorletti, 2014, Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease, Contemp Clin Trials, 37, 301, 10.1016/j.cct.2014.02.002 Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Cusi, 2014, Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease, J Hepatol, 60, 167, 10.1016/j.jhep.2013.07.042 Robinson, 2009, Current patterns of diet in community-dwelling older men and women: results from the Hertfordshire Cohort Study, Age Ageing, 38, 594, 10.1093/ageing/afp121 Browning, 2012, Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish, Am J Clin Nutr, 96, 748, 10.3945/ajcn.112.041343 Burdge, 2000, A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction, Br J Nutr, 84, 781, 10.1017/S0007114500002154 Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5 Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283 Dongiovanni, 2013, PNPLA3 I148M polymorphism and progressive liver disease, World J Gastroenterol, 19, 6969, 10.3748/wjg.v19.i41.6969 Shen, 2015, PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease, J Gastroenterol Hepatol, 30, 139, 10.1111/jgh.12656 Stillwell, 2003, Docosahexaenoic acid: membrane properties of a unique fatty acid, Chem Phys Lipids, 126, 1, 10.1016/S0009-3084(03)00101-4 Tan, 2012, Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging, Neurology, 78, 658, 10.1212/WNL.0b013e318249f6a9 Santoro, 2012, Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake, PLoS One, 7, e37827, 10.1371/journal.pone.0037827 Wojcik, 2014, Modulation of adipocyte differentiation by omega-3 polyunsaturated fatty acids involves the ubiquitin-proteasome system, J Cell Mol Med, 18, 590, 10.1111/jcmm.12194 Nobili, 2013, The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease, J Med Food, 16, 957, 10.1089/jmf.2013.0043 Dongiovanni, 2015, Statin use and nonalcoholic steatohepatitis in at risk individuals, J Hepatol, 63, 705, 10.1016/j.jhep.2015.05.006 Palmer, 2012, Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant, PLoS One, 7, e39362, 10.1371/journal.pone.0039362